Show simple item record

dc.contributor.authorYavuz, Akif Selim
dc.contributor.authorMete, Ozgur
dc.contributor.authorAlpay, Nilufer
dc.contributor.authorNalcaci, Meliha
dc.contributor.authorYenerel, Mustafa Nuri
dc.contributor.authorYildirim, Naciye Demirel
dc.contributor.authorAyer, Mesut
dc.contributor.authorKuecuekkaya, Reyhan Diz
dc.date.accessioned2021-03-05T14:49:33Z
dc.date.available2021-03-05T14:49:33Z
dc.date.issued2007
dc.identifier.citationYildirim N. D. , Ayer M., Kuecuekkaya R. D. , Alpay N., Mete O., Yenerel M. N. , Yavuz A. S. , Nalcaci M., "Leukocytoclastic vasculitis due to thalidomide in multiple myeloma", JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.37, ss.704-707, 2007
dc.identifier.issn0368-2811
dc.identifier.otherav_b8fd0600-9ea7-43aa-bb4e-8efd9a200dac
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/123086
dc.identifier.urihttps://doi.org/10.1093/jjco/hym092
dc.description.abstractThalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects. Thalidomide's most common side effects are constipation, neuropathy, fatigue, sedation, rash, tremor and peripheral edema. We achieved complete responce with a 400 mg/day dose thalidomide therapy in a 58-year-old male patient diagnosed with relapsing refractory multiple myeloma. While continuing thalidomide for sustainable response, the therapy was terminated at the ninth month due to development of leukocytoclastic vasculitis. We describe the case and discuss the place of thalidomide in the treatment of multiple myeloma and the rare occurrence of leukocytoclastic vasculitis during thalidomide therapy in multiple myeloma, since only one such case has been reported in the literature thus far.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleLeukocytoclastic vasculitis due to thalidomide in multiple myeloma
dc.typeMakale
dc.relation.journalJAPANESE JOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume37
dc.identifier.issue9
dc.identifier.startpage704
dc.identifier.endpage707
dc.contributor.firstauthorID184276


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record